Current Protocols · Nov 11, 2026
Screening Strategies Among High‐Risk Populations for Anal Cancer (ACCESS Study) Protocol
By Subbiah R, Bangera SR, Kaonga NN et al.
Background : Anal cancer is a human papillomavirus (HPV)‐associated malignancy that disproportionately affects high‐risk populations, including people living with HIV, men who have sex with men, and women with a history of high‐grade lower genital tract neoplasia. Persistent infection with high‐risk human papillomavirus (hrHPV) is the primary cause of anal high‐grade squamous intraepithelial lesions (aHSIL), the precursor to anal cancer. Current screening approaches, including anal cytology and high‐resolution anoscopy (HRA), have important limitations related to diagnostic performance, cost, accessibility, and the availability of trained providers. There is a critical need for improved screening strategies and biomarkers capable of identifying individuals at greatest risk of persistent disease and progression. Methods : The screening strategies among high‐risk populations for anal cancer (ACCESS) study is a prospective, multisite, longitudinal cohort study that will enroll 500 high‐risk adults from Emory University and the University of Miami. Participants will undergo annual screening for up to 2 years using anal cytology, hrHPV genotyping, CINtec®PLUS dual staining, HRA, and biopsy when indicated. Anal swabs, biopsies, and optional peripheral blood samples will be collected for molecular and immunologic analyses. DNA methylation markers, inflammatory biomarkers, immune profiling by multicolor flow cytometry, and single‐cell RNA sequencing will be evaluated to assess their association with aHSIL prevalence and clearance. Diagnostic performance measures, multivariable regression analyses, and biomarker‐based predictive models will be used to evaluate study outcomes. Discussion : The ACCESS study will evaluate the performance of emerging screening biomarkers and characterize molecular and immune pathways associated with anal carcinogenesis in diverse high‐risk populations. By integrating clinical, epigenetic, immunologic, and environmental data, this study aims to improve risk stratification, identify biomarkers associated with persistent disease, and inform the development of more effective and targeted anal cancer prevention strategies. © 2026 The Author(s). Current Protocols published by Wiley Periodicals LLC.
doi.org/10.1002/cpz1.70518Open accessPubMed 43012141Biomarkers